Uploaded May 2026 | Updated September 2026, 3 weeks ago
People in Eli Lilly’s retatrutide clinical trials are reporting dramatic appetite suppression. So why are gray market retatrutide users reporting almost none — and why are so many of them adding tirzepatide just to feel full?
In this video I break down what I think is happening — and I want to be upfront: I am not a scientist, I am not a chemist, and I have never worn a lab coat in my life. This is my best informed opinion based on publicly available research and what the community is reporting. That said, I think the data tells a pretty compelling story.
The short version: gray market manufacturers have access to retatrutide’s ingredients — the amino acid sequence is in the public patent filings. But what isn’t in the patent is Eli Lilly’s proprietary formulation. The exact GLP-1 to GIP receptor activity ratio that makes the appetite suppression work. Without that recipe, the cookie doesn’t come out right.
The proof? The drug gray market users are reaching for to compensate — tirzepatide — is precisely the drug that would patch a broken GLP-1/GIP ratio. That’s not a coincidence. That’s the clue.
IN THIS VIDEO:
• What clinical trial data actually shows about retatrutide appetite suppression
• Why gray market users are seeing fat burn but not hunger reduction
• The chocolate chip cookie analogy — ingredients vs recipe
• Why tirzepatide is intentionally GIP-dominant (and why that matters)
• How the patent discloses ingredients but not the formulation
• Why the tirzepatide combination behavior is the most important clue
00:00 — Intro: The question nobody is answering
00:45 — Fair warning: I am not a scientist
01:10 — What retatrutide is actually supposed to do
02:41 — The clinical trial appetite data (NEJM + TRIUMPH-4)
05:37 — What gray market users are actually reporting
06:39 — The chocolate chip cookie analogy
07:55 — Why the GLP-1 / GIP ratio is everything
11:04 — The patent problem: ingredients without the recipe
12:31 — Why the tirzepatide combination is the proof
13:49 — Outro: Could I be wrong? Absolutely
SOURCES:
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 2023. nejm.org/doi/full/10.1056/NEJMoa2301972
• Kanu et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes. Diabetes Obes Metab. 2025. dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.70097
• Eli Lilly Phase 3 TRIUMPH-4 Trial Results (Dec 2025). investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
• Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020. pmc.ncbi.nlm.nih.gov/articles/PMC7526454
• Eli Lilly and Company. TRIUMPH-1 Phase 3 Topline Results — Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press Release, May 21, 2026. prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: joinfridays.com/?via=RMZ
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss #reta #retatrutide #peptides
People in Eli Lilly’s retatrutide clinical trials are reporting dramatic appetite suppression. So why are gray market retatrutide users reporting almost none — and why are so many of them adding tirzepatide just to feel full?
In this video I break down what I think is happening — and I want to be upfront: I am not a scientist, I am not a chemist, and I have never worn a lab coat in my life. This is my best informed opinion based on publicly available research and what the community is reporting. That said, I think the data tells a pretty compelling story.
The short version: gray market manufacturers have access to retatrutide’s ingredients — the amino acid sequence is in the public patent filings. But what isn’t in the patent is Eli Lilly’s proprietary formulation. The exact GLP-1 to GIP receptor activity ratio that makes the appetite suppression work. Without that recipe, the cookie doesn’t come out right.
The proof? The drug gray market users are reaching for to compensate — tirzepatide — is precisely the drug that would patch a broken GLP-1/GIP ratio. That’s not a coincidence. That’s the clue.
IN THIS VIDEO:
• What clinical trial data actually shows about retatrutide appetite suppression
• Why gray market users are seeing fat burn but not hunger reduction
• The chocolate chip cookie analogy — ingredients vs recipe
• Why tirzepatide is intentionally GIP-dominant (and why that matters)
• How the patent discloses ingredients but not the formulation
• Why the tirzepatide combination behavior is the most important clue
00:00 — Intro: The question nobody is answering
00:45 — Fair warning: I am not a scientist
01:10 — What retatrutide is actually supposed to do
02:41 — The clinical trial appetite data (NEJM + TRIUMPH-4)
05:37 — What gray market users are actually reporting
06:39 — The chocolate chip cookie analogy
07:55 — Why the GLP-1 / GIP ratio is everything
11:04 — The patent problem: ingredients without the recipe
12:31 — Why the tirzepatide combination is the proof
13:49 — Outro: Could I be wrong? Absolutely
SOURCES:
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 2023. nejm.org/doi/full/10.1056/NEJMoa2301972
• Kanu et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes. Diabetes Obes Metab. 2025. dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.70097
• Eli Lilly Phase 3 TRIUMPH-4 Trial Results (Dec 2025). investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
• Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020. pmc.ncbi.nlm.nih.gov/articles/PMC7526454
• Eli Lilly and Company. TRIUMPH-1 Phase 3 Topline Results — Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press Release, May 21, 2026. prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: joinfridays.com/?via=RMZ
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss #reta #retatrutide #peptides
